CEO Vas Narasimhan said the Novartis pipeline has “significant potential to rejuvenate our portfolio and support mid-single-digit growth post 2029.”
Table of Contents
Swiss pharma giant Novartis says 30 pipeline drugs with ‘significant potential’ will drive long-term growth
CEO Vas Narasimhan said the Novartis pipeline has "significant potential to rejuvenate our portfolio and support mid-single-digit growth post 2029."
